Rethinking the Pipeline: Why Volume Doesn’t Equal Value

Everyone chases a fat pipeline. Yet over the last decade, pipeline volume has decoupled from actual market returns. Why? Because "unmet needs" are moving targets, constantly disrupted by tech, competition, and patient diversity.

Today, market survival requires assets that can withstand these harsh realities.

The new gold standard isn't just finding a niche unmet need; it’s developing a compound that works across multiple pathologies and diverse patient profiles—the Humira model.

That is why we built the Express Tool Box.

It goes beyond basic efficacy and availability. Its ultimate goal is to identify the right drug for any patient—at any stage of disease, across any age group or ethnicity—and clearly track their response.

Here is a quick look at how it transforms the traditional process.

Want to boost a drug's market survival rate by 45%? Stop evaluating biomarkers too early. Our rule is absolute: co-morbid pathology validation comes first.